Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1997-10-10
1999-08-24
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
560158, A61K 3127, C07C27110
Patent
active
059425407
ABSTRACT:
Methods are disclosed for prophylactically and chronically preventing symptomatic depression, neuronal cell injury and cell death in systemic and neurological conditions, populations with cerebrovascular risk factors, and invasive vascular procedures, employing a glycine-site antagonist at the NMDA (N-methyl-D-aspartate) complex e.g., 2-phenyl-1,3-propanediol dicarbamate (felbamate).
REFERENCES:
patent: 5256690 (1993-10-01), Sofia
patent: 5728728 (1998-03-01), Kozachuk
"Abnormalities of Striatal Projection Neurons and N-Methyl-D-Aspartate Receptors in Presymptomatic Huntington's Disease" by Albin, et. al. Brief Report, vol. 322, No. 18, May 1990. vol. 322, pp. 1293-1298.
"Alternative Excitotoxic Hypotheses" by Albin, et. al., Neurology, Apr. 1992. vol. 42, pp. 733-738.
"Amino Acid Abnormalities In Epileptogenic Foci" by Perry, et. al., Neurology, Jul. 1981. vol. 31, pp. 872-876.
"B-Amyloid Peptides Destabilize Calcium Homeostasis and Render Human Cortical Neurons Vulnerable to Excitotoxicity" by Mattson, et. al., The Journal of Neuroscience, Feb. 1992, vol. 12, pp. 376-388.
"B-Amyloid Protein Increases The Vulnerability of Cultered Cortical Neurons to Excitotoxic Damage" by Koh, et. al, Brain Research, 1990, vol. 533, pp. 315-320.
"Behaviorial Effects of Felbamate In Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome)" by Gay, et. al., Psychological Reports, 1995, vol. 77, pp. 1208-1210.
"Ca2+-Dependant And Ca2+- Independent Glutamate Release, Energy Status and Cytosolic Free Ca2+ Concentration in Isolated Nerve Terminals Following Metabolic Inhibition: Possible Relevance to Hypoglycaemia and Anoxia" by Kauppinen, et. al., Neuroscience, vol. 27 No. 1, pp. 175-182, 1988.
"Chemically Induced Hypoglycemia and Anoxia: Relationship to Glutamate Receptor-Mediated Toxicity in Retina" by Zeevalk, et. al., Therapeutics, vol. 253, No. 3, Mar. 1990. pp. 1285-1292.
"Consequences of Epileptic Activity In Vitro" by Thompson, Brain Pathology 3, 1993. pp. 413-419.
"Does Impairment of Energy Metabolism Result in Excitotoxic Neuronal Death in Neurodegenerative I11nesses?" by Beal, American Neurological Assoc., 1992. vol. 31, pp. 119-130.
"Effects of Felbamate on Muscarinic and Metabotropic-Glutamate Agonist-Mediated Responses and Magnesium-Free or 4-Aminopyridine-Induced Epileptiform Activity in Guinea Pig Olfactory Cortex Neurons In Vitro" by Libri, et. al., Jour. of Pharm. & Exper. Thera., 1996, vol. 277, pp. 1759-1769.
"Excess Glutamate Levels in the Crebrospinal Fluid Predict Clinical Outcome of Bacterial Meningitis" by Spranger, et. al., Arch Neurol, vol. 53, Oct. 1996, pp. 992-996.
"Excitatory Amino Acid Neurotoxicity at the N-Methyl-D-Aspartate Receptor in Cultured Neurons: Role of the Voltage-Dependent Magnesium Block" by Cox, et. al., Brain Research, 1989, vol. 499, pp. 267-272.
"Excitatory Amino Acids Are Elevated in Human Epileptic Cerebral Cortex" by Sherwin, et. al., Neurology, Jun. 1988, vol. 38 pp. 920-923.
"Excitoprotective Effect of Felbamate in Cultured Cortical Neurons" by Kanthasamy, et. al., Brain Research, 1995, vol. 705, pp. 97-104.
"Excitotoxicity and Selective Neuronal Loss in Epilepsy" by Meldrum, Brain Pathology, 1993. vol. 3, pp. 405-412.
"Blutamate Becomes Neurotoxic Via the N-Methyl-D-Aspartate Receptor when Intracellular Energy Levels are Reduced" by Novelli, et. al., Brain Research, 1988. vol. 451, pp. 205-212.
"Evidence that Local Non-NMDA Receptors Contribute to Functional Deficits in Contusive Spinal Cord Injury" by Wrathall, et. al., Brain Research, 1992, vol. 586, pp. 140-143.
"Familial Increase in Plasma Glutamic Acid in Epilepsy" by Janjua, et. al., Epilepsy Research, 1992. vol. 11, pp. 37-44.
"Felbamate-Associated Fatal Acute Hepatic Necrosis" by O'Neil, et. al., The American Academy of Neurology, 1996.
"Felbamate Overdoese: A Case Report and Discussion of a New Antiepileptic Drug" by Nagel, et. al., Pediatric Emergency Care, 1995, vol. 11, pp. 369-371.
"Felbamate as Add-On Therapy" by Li, et. al., European Neurology, 1996, vol. 36, pp. 146-148.
"Felbamate Inhibits Dihydropyridine-Sensitive Calcium Channels in Central Neurons" by Stefani, et. al., Journal of Pharmacology and Experimental Therapeutics, vol. 277, No. 1, 1996, pp. 121-127.
"Felbamate Neuroprotection Against CA1 Traumatic Neuronal Injury" by Wallis, et. al., European Jouranl of Pharmacology, 1995, vol. 294 pp. 475-482.
"Felbamate Monotherapy has Stimulant-like Effects in Patients with Epilepsy" by Ketter, et. al., Epilepsy Research, 1996, vol. 23, pp. 129-137.
"Mechanisms of Excitotoxicity in Neurologic Diseases" by Beal, The FASEB Journal, vol. 6, Dec. 1992, pp. 3338-3344.
"Mesial Temporal (Ammon's Horn) Sclerosis as a Common Cause of Epilepsy Aetiology, Treatment, and Prevention" by Falconer, The Lancet, Sep. 1974 pp. 767-770.
N-Methyl-D-Aspartate Receptor Plasticity in Kindling: Quantitative and Qualitative Alternations in the N-Methyl-D-Aspartate Receptor--Channel Complex, by Yeh, et. al., Proc. Natl. Acad. Sci., vol. 86, pp. 8157-8160, Oct. 1989.
"Mitochondrial Impairment Reduces the Threshold for in Vivo NMDA-Mediated Neuronal Death in the Striatum" by Simpson, et. al., Experimental Neurology 121, pp. 57-64, 1993.
"Neurotoxicity at the N-Methyl-D-Aspartate Receptor in Energy-Compromised Neurons" by Henneberry, et. al., Annals New York Academy of Sciences, pp. 225-233.
"Quinolinic Acid in Cerebrospinal Fluid and Serum in HIV-1 Infection: Relationship to Clinical and Neurological Status" by Heyes, et. al., Amer. Neurological Assoc., 1991 vol. 29, pp. 202-207.
"The Role of Excitatory Amino Acids and NMDA Receptors in Traumatic Brian Injury" by Faden, et. al., Science vol. 244, May 1989, pp. 798-800.
"Secretion of Neurotoxins by Mononuclear Phagocytes Infected with HIV-1" by Giulian, et. al., Reports, Dec. 1990. pp. 1593-1596.
"The Severity of Naloxone-Preciitated Opiate withdrawal is Attenuated by Felbamate, a Possible Glycine Antagonist" by Kosten, et. al., Neuropsychopharmacology, vol. 13, No. 4, 1995 pp. 323-333.
"The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential" by Leeson, et. al., Journal of Medicinal Chemistry, vol. 37, No. 24, Nov., 1994.
"Glycine Antagonists: Regulation of the NMDA Receptor-Channel Complex by the Strychnine-Insensitive Glycine Site" by Carter, Drugs of the Future 1992.
"Neuroprotection with Felbamate: a 7- and 28-day Study in Transient Forebrain Ischemia in Gerbils" by Shuaib, et. al., Brain Research 727, 1996.
"Posthypoxic Treatment with Felbamate is Neuroprotective in a Rat Model of Hypoxia-ischemia" by Wasterlain, Neurology 43, Nov. 1993.
"Felbamate Monotherapy for Partial-Onset Seizures: An Active-Control Trial" by Faught, et. al., Neurology 43, Apr., 1993.
"Reduction of Functional Neuronal Connectivity in Long-Term Treated Hypertension" by Mentis, Stroke, vol. 25, No. 3, Mar., 1994.
"Felbamate Monotherapy: Controlled Trial in Patients with Partial Onset Seizures" by Sachdeo, et. al., American Neurological Assoc., 1992.
"Felbamate Protects CA1 Neurons from Apoptosis in a Gerbil Model of Global Ischemia" by Wasterlain, et. al.
"Muscle Relaxant Action of Excitatory Amino Acid Antagonists" by Schwartz, et. al., 1993.
"Efficacy of Felbamate in Therapy for Partial Epilepsy in Children" by Carmant, et. al., The Journal of Pediatrics, Sep., 1994.
"Prophylactic Neuroprotection for Cerebral Ischemia" by Fisher, Stroke, vol. 25, No. 5, May, 1994.
"Brain Atrophy in Hypertension--A Volumetric Magnetic Resonance Imaging Study" by Salerno, et. al., Hypertension, vol. 20, No. 3, Sep., 1992.
Aulakh Charanjit S.
Rhoa Joseph A.
Rotman Alan L.
LandOfFree
Methods of providing symptomatic and prophylactic neuroprotectio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of providing symptomatic and prophylactic neuroprotectio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of providing symptomatic and prophylactic neuroprotectio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-467360